Archives

CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients with Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase

Melissa Johnson, Jordi Rodon Ahnert, Nehal Lakhani, Rachel E. Sanborn, Anthony El-Khoueiry, Navid Hafez, Hirva Mamdani, Valentina Boni, Henry Castro, Alison L. Hannah, Alexander Spira. Presented at the IASLC 2020 World Conference on Lung Cancer Singapore virtual meeting, January 28-31, 2021.

Learn More

Intratumoral Activation and Phase 1/2 Clinical Activity of Praluzatamab Ravtansine (CX-2009), a Probody® Drug Conjugate (PDC) Targeting CD166

Liu J, Zein IA, Dang T, Lyman SK, Wang S, Spira A, Uboha N, LoRusso P, Fidler MJ, Meric-Bernstam F, Arkenau T, Nagasaka M, Desnoyers LR, Kavanaugh WM, Paton VE, Hannah AL, Boni V. Poster presented at the San Antonio Breast Cancer Symposium®, December 8-11, 2020.

Learn More

CX-2043, an EpCAM-Targeting Probody Drug Conjugate, Demonstrates Anti -Tumor Activity with a Favorable Safety Profile in Preclinical Models

Bob Y. Liu, Joel Shen, Wendy Yu, Chaoran Jing, Sharmi Saha, Vangipuram Rangan, Jennifer Richardson, Yimao Liu, Steven Boule, Jacquelynn Lucas, Olga Ab, Stuart Hicks, W. Michael Kavanaugh, Siew Schleyer, Marcia Belvin. Poster presented at the 32nd EORTC-NCI-AACR Symposium, October 24-25, 2020.

Learn More

Harnessing the Power of CytomX’s Probody® Technology to Drug the Undruggable

Alison L. Hannah, MD. Presented at the World ADC Digital Conference, September 15-18, 2020.

Learn More

Utilizing Probody® Technology to Develop Therapeutics to Undruggable Targets

Bob Liu, Ph.D. Presented at the World ADC Digital Conference, September 15-18, 2020.

Learn More

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

Autio KA, Boni V, Humphrey RW, Naing A. Clin Cancer Res. 2020 26(5): 984-989. doi:10.1158/1078-0432.CCR-19-1457.

Learn More

Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Giesen D, Broer LN, Lub-de Hooge MN, et al. Clin Cancer Res. January 17, 2020; doi: 10.1158/1078-0432.CCR-19-3137.

Learn More

CX-2009, a CD166-Directed PROBODY Drug Conjugate (PDC): Results From the First-in-Human Study in Patients With Advanced Cancer Including Breast Cancer

Valentina Boni, Howard Burris, Joyce Liu, Alexander Spira, Hendrik-Tobias Arkenau, Mary Josephine Fidler, Lee Rosen, Randy F. Sweis, Nataliya Uboha, Rachel E. Sanborn, Bert O’Neil, James Harding, Patricia LoRusso, Amy Weise, Javier Garcia-Corbacho, Ivan Victoria, Mark Stroh, Rachel Li, Alison Hannah, Ginny Paton, Funda Meric-Bernstam. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More